Overview A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA) Status: Completed Trial end date: 2012-12-01 Target enrollment: Participant gender: Summary To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis. Phase: Phase 2 Details Lead Sponsor: Asahi Kasei Pharma Corporation